We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bionostics | LSE:BIO | London | Ordinary Share | GB0008381823 | ORD 25P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 29.75 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 29.75 | GBX |
Biofocus (BIO) Share Charts1 Year Biofocus Chart |
|
1 Month Biofocus Chart |
Intraday Biofocus Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 15/1/2016 | 04:19 | US BIOTECH | 2 |
| 06/8/2013 | 18:32 | Microcap Biotech Thread (SAR,PYC,VAL,RENE,MEDU,SUMM) | 9 |
| 06/8/2013 | 18:30 | Biotech Bull thread- charts please | 27 |
| 22/2/2008 | 14:16 | Bionostics( formely ferraris) | 320 |
| 01/9/2007 | 22:56 | Bionostics | 50 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 06/12/2012 00:08 by mrsapeslaptop SLN is stonking away today and looks like a breakout.have to confess I really dont understand the technology at all. but my best performing share this year. |
Posted at 28/11/2012 22:20 by moneymunch none of the following UK Bio's are listed (yet), but could be worth watching....????4 November 2012 £39m Biomedical Catalyst funding will speed-up development of new healthcare technologies Grants from the government-backed Biomedical Catalyst totalling £39 million have been awarded to 32 projects led by small and medium-sized businesses (SMEs) and universities to accelerate the development of innovative solutions to healthcare challenges. The 22 business-led projects will be managed by: Arecor Ltd, Bioinduction Ltd, Cantab Biopharmaceuticals Ltd, Creabilis Ltd, Cyclacel Ltd, Discuva Ltd, ELISHA Systems Ltd, Glide Pharmaceutical Technologies Ltd, ImmunoBiology Ltd, Immunocore Ltd, Intelligent Fingerprinting Ltd, IXICO Ltd, Kalvista Pharmaceuticals Ltd, Medical Research Council Technology, Modern Biosciences plc, OJ-Bio Ltd, Pharminox Ltd, Prosonix Ltd, PsiOxus Therapeutics Ltd, QuantuMDx Group Ltd, Sentinel Oncology Ltd and UB Pharma. |
Posted at 19/7/2011 00:54 by melv3 Is anyone here invested in MEDU? doesn't seem to be much interest compared to other biotech shares (SAR,PYC,SUMM, VAL etc) but the share looks to have fantastic potential. |
Posted at 23/5/2011 08:34 by addis abbaba Intraday MACD on SUMM |
Posted at 21/11/2009 22:57 by theape2 a site for my favourite bullish biotech charts. all suggestions welcome (Bio sector, break above the 200d ma on good volume, preferably low cap and cash for 6 months). and ill post them upin the meantime back to what a good thread is all about. buffoonery, making money, and pratting about |
Posted at 06/12/2007 12:00 by tommya Great news for shareholders but what should they do now?Price seems to have stabilised at 28p, with a sell price available at 27.5p, i.e. around 8% below the 30p offer. Should holders: i) sell. ii) hold The following outlines the timetable from this morning's RNS: "15.2 Anticipated Timetable Bionostics anticipates that it will despatch the Scheme Document to Bionostics Shareholders and, for information only, to holders of options granted under the Bionostics Share Schemes on or about 15 December 2007, but in any event within the next 28 days (or such later date as may be agreed with the Panel); that the Court Meeting and EGM will take place during January 2008; and subject to the Scheme becoming unconditional and effective in accordance with its terms, the Effective Date will occur at the end of January 2008. The timing of events which relate to the implementation of the Scheme is, however, subject to the approval of the Court and is therefore subject to change. A full anticipated timetable will be set out in the Scheme Document. If the Proposals do not become effective by 29 February 2008, the Proposals will lapse except where the approval of Bionostics Shareholders at the Court Meeting and the EGM is obtained before this date, in which case the longstop date for the Proposals may be extended to such later date as NAV Bidco and Bionostics may agree and, if appropriate, the Court may approve." The market is discounting 8% of value due to the uncertainty of the deal going through between now and end February; i.e. attributing an 8% chance of it fallling through. All Bio directors have signed up to the proposal, as have NAV and Mannheim Holdings, who have 10.3% of share capital. Mannheim have stated that their "irrevocable undertaking will only lapse if a competing offer is made for the entire issued share capital of Bionostics which exceeds the value of the Offer by ten per cent. or more." So, what chance a counterbid by a third party? |
Posted at 04/12/2007 17:47 by aquilla This share never ceases to amaze. It is on the radar of only a few investors, ignored by the rest. In some ways not surprising, with a market cap of a mere £7m and a chart that looks horrendous. Indeed it has never caught the imagination in the way that some small caps have (remember RTD?). When I started the first BIO thread (and I originally got in back in January at 23p) there would be a couple of posts a week, if that. But what is surprising is that the share price is now languishing at 14.5p, given the fact that there are still ongoing talks which might lead to an offer of 30p and that, aside from the bid element, the fundamentals of the company offer hope for the future. With a new CEO with a turn-around track record brought in last year, the loss making divisions gone and two cash generative divisions left one would have expected the share price to have done more. Yes, there is the debt but, as has been pointed out before, hopefully the cash generative divisions will reduce this sharply. Part of the problem lies, I believe, with the illiquidity of the share. A small cap already, most of the shares are held by institutions. NMS at the moment is 1500, and 5000 traded today would have cleared the order book. A pathetic amount. I have indeed found that it can be traded in much larger quantities, without moving the share price against the trader, but how many private investors have the knowledge or persuasive powers to go down that route? Is this going to turn out to have been a good investment? Time will tell, but in the meantime we remain in the doldrums. |
Posted at 29/11/2007 12:35 by gjcorr BlackPerlSomething doesn't make sense to me. This share has been drifting down for a while. If you really KNEW or were even confident of a buyout at 30p, you would let it drift down and top up. I can't believe you are so altruistic that you spread your news, knowing it may keep the share price up and deny you a chance yo buy at lower prices. Some possibilities come to mind.. 1)You are ramping, and shorting this on price increases because you know the buyout is not going ahead and ultimately expect a share price crash. 2) You know there is a buyout but share price drops, will lower the offer price, hence you are trying to talk up the price 3) You don't know anything about the buyout, but you are seroiusly long in this stock and depressed at seeing your holding shrink in value, so you ramp |
Posted at 30/9/2007 18:32 by aquilla Well, it looks like the news is out! In today's Sunday Times:"The activist fund management group North Atlantic Value is poised to launch a takeover bid for Bionostics valuing the medical diagnostics firm at about £15m. According to bankers, North Atlantic, which is backed by a group of investors, is planning to bid 30p a share for Bionostics. The offer is a 30% premium to the share price of 23p on Friday. North Atlantic is already Bionostic's largest shareholder with a 26.76% stake held in four of the funds it manages. Bionostics shares have slumped by 85% since hitting 170p in 2004. The group sold off its cardiac monitoring assets in June 2006 to Spacelabs Healthcare for £14m. However, in April Bionostics announced it had swung to a £490,000 loss for the first six months of the year against a profit of £536,000 a year earlier." I spoke to the company earlier in the week and got a pretty strong hint that news (one way or the other) would be coming soon. The figure also coincides with the maximum price that N.Atlantic previously paid for the shares and what I thought the offer price would be. Interesting that there was a sharp drop in share price just before the conclusion of talks (if this turns out to be the case). I mentioned in a previous post the case of RTD where exactly the same thing happened: a sharp drop, designed to trigger stop losses and make shareholders think bad news was on the way, only to be followed by the announcement of successful conclusion of talks! Ps I think the share price will rocket tomorrow. |
Posted at 13/7/2007 03:52 by tunturiflyer On quite days, someone seems to be selling in lumps of 1250 and 750. - presumably the sells are something to do with North Atlantic Value. Been happening like this for months, even when the price was 22p. Result is that the share price drops a couple of pence. Usually, someone (like me) picks up a few thousand, and the share price returns to what it was. However, I've got enough in BIO.Paul Hill reckons that BIO are worth 50p+ to an acquirer, since you save all the costs of listing on the LSE, plus all the directors and non-execs. However, usually people reckon a 40% uplift on the share price in the event of an acquisition, so suggests an share price of about 32. Yet the chairman has a bunch of options at 34p. Folk do seem to be losing patience, so it will probably sink some more, before something happens. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
